본문 바로가기
KERD
논문KCI 등재

The Effect of Helicobacter pylori on Epidermal Growth Factor Receptor- Induced Signal Transduction and the Preventive Effect of Celecoxib in Gastric Cancer Cells

김지연|박지현|김주성|이동호|김재연|장현|김나영|김정목|정현채
거트앤리버 소화기연관학회협의회|2013.09|Gut and Liver|제7권 제5호|pp. 552-559

1

조회

0

다운로드

1

인용

0

참고문헌

키워드

epidermal growth factor; Celecoxib

초록

Background/Aims: Helicobacter pylori infection induces cyclooxygenase-2 (COX-2) and epidermal growth factor receptor (EGFR) overexpression, and these factors may engage in cross-talk. The aim of the present study was to evaluate the effect of H. pylori on EGFR signaling pathways and to determine whether celecoxib has an inhibitory effect on this pathway. Methods: The AGS cell line was cocultured with H. pylori G27 and the isogenic cagE- mutant. The expression of COX-2, EGFR, heparin binding-epidermal growth factor (HB-EGF),and transforming growth factor-β (TGF-β) was measured by real time-polymerase chain reaction (RT-PCR). Next, Western blot analyses of COX-2, EGFR, total Akt, phosphorylated Akt (pAkt), and phosphorylated glycogen synthase kinase-3β(pGSK3β) were performed after incubating H. pylori-treated AGS cells for 24 hours with various concentrations of celecoxib (0, 10, 20, and 30 μmol/L). Results: H. pylori infection upregulated the mRNA levels of COX-2, EGFR, HB-EGF, and TGF-β, as detected by RT-PCR. However, AGS cells treated with cagE- mutants, which have a defective type IV secretion system, did not exhibit EGFR upregulation. Celecoxib had inhibitory effects on the H. pylori-induced overexpression of COX-2 (p=0.015), EGFR (p=0.025), pAkt (p=0.025), and pGSK3β (p=0.029) by Western blot analysis. Conclusions:H. pylori with an intact type IV secretion system activated the COX-2 and EGFR-Akt pathways in the AGS cell line. As celecoxib exhibited inhibitory effects on the EGFR signaling pathway, the cross-talk of COX-2 and EGFR likely mediates H. pylori-induced gastric cancer

Abstract

Background/Aims: Helicobacter pylori infection induces cyclooxygenase-2 (COX-2) and epidermal growth factor receptor (EGFR) overexpression, and these factors may engage in cross-talk. The aim of the present study was to evaluate the effect of H. pylori on EGFR signaling pathways and to determine whether celecoxib has an inhibitory effect on this pathway. Methods: The AGS cell line was cocultured with H. pylori G27 and the isogenic cagE- mutant. The expression of COX-2, EGFR, heparin binding-epidermal growth factor (HB-EGF),and transforming growth factor-β (TGF-β) was measured by real time-polymerase chain reaction (RT-PCR). Next, Western blot analyses of COX-2, EGFR, total Akt, phosphorylated Akt (pAkt), and phosphorylated glycogen synthase kinase-3β(pGSK3β) were performed after incubating H. pylori-treated AGS cells for 24 hours with various concentrations of celecoxib (0, 10, 20, and 30 μmol/L). Results: H. pylori infection upregulated the mRNA levels of COX-2, EGFR, HB-EGF, and TGF-β, as detected by RT-PCR. However, AGS cells treated with cagE- mutants, which have a defective type IV secretion system, did not exhibit EGFR upregulation. Celecoxib had inhibitory effects on the H. pylori-induced overexpression of COX-2 (p=0.015), EGFR (p=0.025), pAkt (p=0.025), and pGSK3β (p=0.029) by Western blot analysis. Conclusions:H. pylori with an intact type IV secretion system activated the COX-2 and EGFR-Akt pathways in the AGS cell line. As celecoxib exhibited inhibitory effects on the EGFR signaling pathway, the cross-talk of COX-2 and EGFR likely mediates H. pylori-induced gastric cancer

참고문헌 (50)

  1. Correa P, "Helicobacter pylori and gastric cancer: state of the art", Cancer Epidemiol Biomarkers Prev, 5, pp.477~481 (1996)
  2. Peek RM Jr, "Helicobacter pylori and gastrointestinal tract adenocarcinomas", Nat Rev Cancer, 2, pp.28~37 (2002)
  3. Stoicov C, "Molecular biology of gastric cancer: Helicobacter infection and gastric adenocarcinoma: bacterial and host factors responsible for altered growth signaling", Gene, 341, pp.1~17 (2004)
  4. Cover TL, "Helicobacter pylori VacA, a paradigm for toxin multifunctionality", Nat Rev Microbiol, 3, pp.320~332 (2005)
  5. Fischer W, "Systematic mutagenesis of the Helicobacter pylori cag pathogenicity island: essential genes for CagA translocation in host cells and induction of interleukin-8", Mol Microbiol, 42, pp.1337~1348 (2001)
  6. Williams C, "The role of COX-2 in intestinal cancer", Ann N Y Acad Sci, 889, pp.72~83 (1999)
  7. Yamac D, "Cyclooxygenase-2 expression and its association with angiogenesis, Helicobacter pylori, and clinicopathologic characteristics of gastric carcinoma", Pathol Res Pract, 204, pp.527~536 (2008)
  8. Tatsuguchi A, "Cyclooxygenase-2 expression correlates with angiogenesis and apoptosis in gastric cancer tissue", Hum Pathol, 35, pp.488~495 (2004)
  9. "Involvement of Ras and AP-1 in Helicobacter pylori-Induced Expression of COX-2 and iNOS in Gastric Epithelial AGS Cells", Digestive Diseases And Sciences, 55, pp.988~996 (2010), Springer
  10. Wu WK, "Cyclooxygenase-2 in tumorigenesis of gastrointestinal cancers: an update on the molecular mechanisms", Cancer Lett, 295, pp.7~16 (2010)
  11. Hu PJ, "Chemoprevention of gastric cancer by celecoxib in rats", Gut, 53, pp.195~200 (2004)
  12. "The anti-cancer effect of COX-2 inhibitors on gastric cancer cells", DIGESTIVE DISEASES AND SCIENCES, 52, pp.1713~1721 (2007), SPRINGER
  13. Wang WH, "Non-steroidal anti-inflammatory drug use and the risk of gastric cancer: a systematic review and meta-analysis", J Natl Cancer Inst, 95, pp.1784~1791 (2003)
  14. Chang F, "Involvement of PI3K", Akt pathway in cell cycle progression, apoptosis, and neoplastic transformation: a target for cancer chemotherapy, 2003, pp.17, 590~603
  15. Liu H, "Anticancer effect of celecoxib via COX-2 dependent and independent mechanisms in human gastric cancers cells", Dig Dis Sci, 54, pp.1418~1424 (2009)
  16. "Anti-gastric cancer effects of celecoxib, a selective COX-2 inhibitor, through inhibition of Akt signaling", JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 24, pp.480~487 (2009), Blackwell Publishing
  17. Caputo R, "Helicobacter pylori VacA toxin up-regulates vascular endothelial growth factor expression in MKN 28 gastric cells through an epidermal growth factor receptor-, cyclooxygenase-2-dependent mechanism", Clin Cancer Res, 9, pp.2015~2021 (2003)
  18. Zheng L, "Molecular basis of gastric cancer development and progression", Gastric Cancer, 7, pp.61~77 (2004)
  19. Keates S, "Transactivation of the epidermal growth factor receptor by cag+ Helicobacter pylori induces upregulation of the early growth response gene Egr-1 in gastric epithelial cells", Gut, 54, pp.1363~1369 (2005)
  20. Tabassam FH, "Helicobacter pylori activate epidermal growth factor receptor- and phosphatidylinositol 3-OH kinase-dependent Akt and glycogen synthase kinase 3beta phosphorylation", Cell Microbiol, 11, pp.70~82 (2009)
  21. Yan F, "Epidermal growth factor receptor activation protects gastric epithelial cells from Helicobacter pylori-induced apoptosis", Gastroenterology, 136, pp.1297~1307 (2009)
  22. 김나영, "Analysis of Gene Expression Profile of AGS Cells Stimulated by Helicobacter pylori Adhesion", Gut and Liver, 1(1), pp.40~48 (2007), 거트앤리버 발행위원회
  23. Vivanco I, "The phosphatidylinositol 3-Kinase AKT pathway in human cancer", Nat Rev Cancer, 2, pp.489~501 (2002)
  24. Normanno N, "Epidermal growth factor receptor (EGFR) signaling in cancer", Gene, 366, pp.2~16 (2006)
  25. Saadat I, "Helicobacter pylori CagA targets PAR1", MARK kinase to disrupt epithelial cell polarity, 2007, pp.447, 330~333
  26. Peek RM Jr, "Helicobacter pylori cagA+ strains and dissociation of gastric epithelial cell proliferation from apoptosis", J Natl Cancer Inst, 89, pp.863~868 (1997)
  27. Backert S, "Role of type IV secretion in Helicobacter pylori pathogenesis", Cell Microbiol, 10, pp.1573~1581 (2008)
  28. Censini S, "cag, a pathogenicity island of Helicobacter pylori, encodes type I-specific and disease-associated virulence factors", Proc Natl Acad Sci U S A, 93, pp.14648~14653 (1996)
  29. Shibata W, "CagA protein secreted by the intact type IV secretion system leads to gastric epithelial inflammation in the Mongolian gerbil model", J Pathol, 210, pp.306~314 (2006)
  30. Yin Y, "Helicobacter pylori potentiates epithelial:mesenchymal transition in gastric cancer: links to soluble HB-EGF, gastrin and matrix metalloproteinase-7", Gut, 59, pp.1037~1045 (2010)
  31. Maehara Y, "Role of transforming growth factor-beta 1 in invasion and metastasis in gastric carcinoma", J Clin Oncol, 17, pp.607~614 (1999)
  32. Vagenas K, "TGFbeta1, TGFbeta2, and TGFbeta3 protein expression in gastric carcinomas: correlation with prognostics factors and patient survival", J Surg Res, 139, pp.182~188 (2007)
  33. 장태정, "Cyclooxygenase-2 Expression Is Related to the Epithelial-to-Mesenchymal Transition in Human Colon Cancers", Yonsei Medical Journal, 50(6), pp.818~824 (2009), 연세대학교의과대학
  34. Liu M, "EGFR signaling is required for TGF-beta 1 mediated COX-2 induction in human bronchial epithelial cells", Am J Respir Cell Mol Biol, 37, pp.578~588 (2007)
  35. Ogunwobi OO, "Cyclooxygenase-2 and Akt mediate multiple growth-factor-induced epithelial-mesenchymal transition in human hepatocellular carcinoma", J Gastroenterol Hepatol, 27, pp.566~578 (2012)
  36. Dannenberg AJ, "Cyclooxygenase-2 and epidermal growth factor receptor: pharmacologic targets for chemoprevention", J Clin Oncol, 23, pp.254~266 (2005)
  37. Futagami S, "Chemopreventive effect of celecoxib in gastric cancer", Inflammopharmacology, 15, pp.1~4 (2007)
  38. Yang P, "Aspirin use and the risk of gastric cancer: a meta-analysis", Dig Dis Sci, 55, pp.1533~1539 (2010)
  39. Juni P, "Risk of cardiovascular events and rofecoxib: cumulative meta-analysis", Lancet, 364, pp.2021~2029 (2004)
  40. Kimmel SE, "Patients exposed to rofecoxib and celecoxib have different odds of nonfatal myocardial infarction", Ann Intern Med, 142, pp.157~164 (2005)
  41. Solomon SD, "Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention", N Engl J Med, 352, pp.1071~1080 (2005)
  42. Graham DJ, "Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study", Lancet, 365, pp.475~481 (2005)
  43. Wong BC, "Effects of selective COX-2 inhibitor and Helicobacter pylori eradication on precancerous gastric lesions", Gut, 61, pp.812~818 (2012)
  44. Arjona-Sanchez A, "Effects of capecitabine and celecoxib in experimental pancreatic cancer", Pancreatology, 10, pp.641~647 (2010)
  45. Aruajo AM, "Phase II study of celecoxib with cisplatin plus etoposide in extensive-stage small cell lung cancer", Cancer Invest, 27, pp.391~396 (2009)
  46. Csiki I, "Targeting cyclooxygenase-2 in recurrent non-small cell lung cancer: a phase II trial of celecoxib and docetaxel", Clin Cancer Res, 11, pp.6634~6640 (2005)
  47. El-Rayes BF, "Phase-II study of dose attenuated schedule of irinotecan, capecitabine, and celecoxib in advanced colorectal cancer", Cancer Chemother Pharmacol, 61, pp.283~289 (2008)
  48. Pan CX, "A phase II trial of irinotecan, 5-fluorouracil and leucovorin combined with celecoxib and glutamine as first-line therapy for advanced colorectal cancer", Oncology, 69, pp.63~70 (2005)
  49. Chan E, "Dual blockade of the EGFR and COX-2 pathways: a phase II trial of cetuximab and celecoxib in patients with chemotherapy refractory metastatic colorectal cancer", Am J Clin Oncol, 34, pp.581~586 (2011)
  50. Kao J, "Phase 1 trial of concurrent erlotinib, celecoxib, and reirradiation for recurrent head and neck cancer", Cancer, 117, pp.3173~3181 (2011)

관련 논문AI추천

Jak1/Stat3 Is an Upstream Signaling of NF-κB Activation in Helicobacter pylori-Induced IL-8 Production in Gastric Epithelial AGS Cells김혜영, 임주원, 차보람연세대학교의과대학 · Yonsei Medical Journal2015 · 제56권 제3호Effects of the Helicobacter pylori Virulence Factor CagA and Ammonium Ion on Mucins in AGS CellsDing Shi, Dong Wu, Wu-jie Chen, Xiaoyu Zhang, Yong-pan Liu연세대학교의과대학 · Yonsei Medical Journal2018 · 제59권 제5호Co-Expression of Cox-2, C-Met and β-catenin in Cells Forming Invasive front of Gallbladder Cancer이호, 문우성, 박호성, 장규윤, Andrzej S. Tarnawski, Kyung Ryoul Kim, Rama Pai대한암학회 · Cancer Research and Treatment2005 · 제37권 제3호Helicobacter pylori Eradication Downregulates Cellular Inhibitor of Apoptosis Protein 2 in Gastric Carcinogenesis신은, 윤혁, 강경훈, 김나영, 김보경, 김상균, 이혁준, 정현채거트앤리버 소화기연관학회협의회 · Gut and Liver2017 · 제11권 제1호Decreased Expression of 15-hydroxyprostaglandin Dehydrogenase in Gastric Carcinomas장태정, 정기훈, 지예섭연세대학교의과대학 · Yonsei Medical Journal2008 · 제49권 제6호Helicobacter pylori-derived outer membrane vesicles stimulate interleukin 8 secretion through nuclear factor kappa B activationEun Young Ze, Jae Gyu Kim, Jae Yong Park, Mun Sun Choi, Tae-Seop Shin대한내과학회 · The Korean Journal of Internal Medicine2021 · 제36권 제4호

이 간행물의 다른 논문 (18건)

Role of Ghrelin in the Pathophysiology of Gastrointestinal DiseaseJustin Che-Yuen Wu, Cynthia K. Cheungpp. 505-512SOX9 Is Highly Expressed in Nonampullary Duodenal Adenoma and Adenocarcinoma in HumansKentaro Sugano, Hironori Yamamoto, Yoshimasa Miura, Hirotsugu Sakamoto, Hiroyuki Mutoh, Miho Sashikawapp. 513-518Association between Plasma Levels of Plasminogen Activator Inhibitor-1 and Colorectal Neoplasms장동경, 김은란, 김진용, 김재준, 이종철, 이준행, 임연정, 양문희, 김영호, 손희정pp. 519-523Prevalence of Proximal Serrated Polyps and Conventional Adenomas in an Asymptomatic Average-Risk Screening Population김윤화, 장재영, 이창균, 심재준pp. 524-531Visceral Obesity as a Risk Factor for Left-Sided Diverticulitis in Japan: A Multicenter Retrospective StudyTetsuya Matsuura, Hirokazu Takahashi, Eiji Yamada, Hidenori Ohkubo, Takuma Higurashi, Eiji Sakai, Hiroki Endo, Eri Uchida, Emi Tanida, Nobuyoshi Izumi, Akira Kanesaki, Yasuo Hata, Atsushi Nakajima, Nobutaka Fujisawa, Kazuto Komatsu, Shin Maedapp. 532-538
원문 보기